PTK2 and neoplasm: FAK inhibitor VS‐4718 treatment further reduced tumour fibrosis and numbers of infiltrating immunosuppressive populations of myeloid‐derived suppressor cells (MDSCs), tumour‐associated macrophages (TAMs) and regulatory T‐cells, sensitising the KPC mouse model to checkpoint immunotherapy 25.